Canaccord analyst Whitney Ijem lowered the firm’s price target on Vertex Pharmaceuticals to $371 from $378 and keeps a Sell rating on the shares. The firm said the big news out of the company’s 4Q report was Ph3 data from the vanza triple, which was successful across 3 Ph3 trials, which was broadly expected.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $420 from $397 at RBC Capital
- Vertex Pharmaceuticals downgraded to In Line from Outperform at Evercore ISI
- Vertex Pharmaceuticals price target raised to $457 from $397 at H.C. Wainwright
- Vertex Pharmaceuticals price target lowered to $275 from $446 at Barclays
- Vertex Pharmaceuticals sees FY24 revenue $10.55B-$10.75B, consensus $10.61B
